- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04638387
PB125, Osteoarthritis, Pain, Mobility, and Energetics
September 10, 2022 updated by: Karyn Hamilton, Colorado State University
Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activation, Mobility, and Energetics: A Pilot and Feasibility Clinical Trial of PB125 Treatment for Improving Musculoskeletal and Pain Outcomes in Osteoarthritis
Nuclear factor erythroid 2-related factor 2 (Nrf2) is an important regulator in the body.
It controls how well cells protect themselves against stress.
PB125 (Pathways Bioscience) is a plant based activator of this important regulator Nrf2.
PB125 is made up of three plant extracts (rosemary, ashwagandha, and Sophora japonica) so that it contains these things; 1. Carnosol, 2. Withaferin A, and 3. Luteolin.
Carnosol comes from rosemary leaves.
Rosemary is a spice often used in Italian foods and grown in many herb gardens all around Fort Collins.
Withaferin A comes from the medicinal plant Withania somnifera, also called ashwagandha.
Ashwaganda is commonly known as "Indian Winter cherry" or "Indian Ginseng" and it is one of the most important herbs of Ayurveda (the traditional system of medicine in India) used for millennia.
Finally, luteolin is found widely in plants including those present in the diet (peppers, onions, celery, herbs/spices).
Some people purchase these herbs commercially, and take them on their own for a variety of purposes.
Typically, when you buy them, they will be in much higher doses than they are in PB125.
What makes PB125 different is that very low doses of each of the 3 components work together-synergistically-to activate Nrf2 and increase the ability of cells to respond to stress.
It is unknown if there are any benefits to taking PB125 and the risks are currently unknown.
The purpose of this study is to examine changes in muscle, in joint pain, in mobility (standing and walking) and in leg strength that occur after consuming PB125 every day for 3 months.
We want to make these measurements in people who have been diagnosed with mild to moderate osteoarthritis-a degenerative joint disease-in their knees.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Preventing or slowing age-related decline in musculoskeletal function is important for maintaining mobility and independence.
In the US, osteoarthritis (OA) is the primary cause of disability in adults, with no medical or surgical therapeutic intervention known to restore the degenerated cartilage.
The loss of skeletal muscle mass and function with age, is also linked to increased risk of other diseases, risk of falls, and decreased quality of life.
Therefore, OA and muscle loss together are primary contributors to age-related decreases in mobility and independence.
Evidence suggests a decrease in muscle quality is associated with or precedes primary knee OA, suggesting that these two conditions may share a common cause.
We will treat 50-65 year old people with mild or moderate OA in both knees, and reported loss of muscle strength, with a supplement already available for use in humans to reduce oxidative stress and inflammation.
The supplement is called PB125.
In this pilot clinical trial, we will measure the ability of muscle to make energy, measure mobility (walking and standing) and strength, and assess pain following PB125 or placebo treatment.
Study Type
Interventional
Enrollment (Actual)
4
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Colorado
-
Fort Collins, Colorado, United States, 80523-1582
- Colorado State University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
48 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- bilateral knee osteoarthritis
Exclusion Criteria:
- smoking
- pregnant/breastfeeding
- BMI >30
- known liver, renal, heart disease, diabetes, autoimmune disease, cancer
- use of methotrexate, etanercept, infliximab, leflunomide, plaquenil
- recent serious illness
- intraarticular stem cell injection
- intraarticular steroid or hyaluronic acid injection within 4 months
- current enrollment in another trial of investigational drugs
- known hypersensitivity to ashwagandha, luteolin, rosemary, or rice flour
- use of anticoagulants or known bleeding disorder
- unwillingness to comply with protocol
- plans for knee replacement in the next 3 years
- unable to complete mobility testing without ambulatory aid
- unable to climb 1-2 flights or stairs without stopping/shortness of breath/discomfort
- blood product transfusion within 30 days
- unable to provide legal consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PB125
Twice daily oral administration of 1 capsule of PB125 (Pathways Bioscience).
Treatment will last 12 weeks.
|
Nrf2 activator containing active ingredients carnosol, withaferin A, and luteolin.
|
Placebo Comparator: Placebo
Twice daily oral administration of 1 capsule of rice flour placebo (Pathways Bioscience).
Treatment will last 12 weeks.
Because of pandemic restricting study time frame, enrollment will favor the experimental arm in this pilot study
|
Placebo comparator to P125
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mobility-6 min self-paced walk
Time Frame: Change from baseline at 12 weeks
|
Change in Distance walked
|
Change from baseline at 12 weeks
|
Mobility-sit to stand
Time Frame: Change from baseline at 12 weeks
|
Change in Time for 5 sit to stand repetitions
|
Change from baseline at 12 weeks
|
Mobility-static balance
Time Frame: Change from baseline at 12 weeks
|
Yes/No ability to complete 30 sec trials with eyes open or closed on firm and foam surfaces
|
Change from baseline at 12 weeks
|
Mobility-6 min fast-paced walk
Time Frame: Change from baseline at 12 weeks
|
Change in Distance walked
|
Change from baseline at 12 weeks
|
Intermittent and Constant Knee Pain
Time Frame: Change weekly for 12 weeks
|
Weekly change in Intermittent and Constant Pain Score (ICOAP) 11 question survey of pain on a 0-4 scale
|
Change weekly for 12 weeks
|
Energetics-Submaximal Oxygen Consumption
Time Frame: Change from baseline at 12 weeks
|
Change in oxygen (O2) flux in permeabilized muscle fibers at submaximal adenosine diphosphate (ADP) concentrations
|
Change from baseline at 12 weeks
|
Energetics-Maximal Oxygen Consumption
Time Frame: Change from baseline at 12 weeks
|
Change in O2 flux in permeabilized muscle fibers at maximal ADP concentrations
|
Change from baseline at 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Energetics-hydrogen peroxide emission
Time Frame: Change from baseline at 12 weeks
|
Change in Hydrogen peroxide emission in permeabilized muscle fibers
|
Change from baseline at 12 weeks
|
Bone Mineral Density
Time Frame: Change from baseline at 12 weeks
|
Bone mineral density via dual x-ray absorptiometry (DEXA)
|
Change from baseline at 12 weeks
|
Knee Range of Motion
Time Frame: Change from baseline at 12 weeks
|
Change in active and passive bilateral knee range of motion
|
Change from baseline at 12 weeks
|
Leg extensor strength
Time Frame: Change from baseline at 12 weeks
|
Change in maximal force generated during knee extension
|
Change from baseline at 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 3, 2020
Primary Completion (Actual)
September 1, 2021
Study Completion (Actual)
September 1, 2021
Study Registration Dates
First Submitted
November 12, 2020
First Submitted That Met QC Criteria
November 16, 2020
First Posted (Actual)
November 20, 2020
Study Record Updates
Last Update Posted (Actual)
September 14, 2022
Last Update Submitted That Met QC Criteria
September 10, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19-9100H
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis, Knee
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
The Hong Kong Polytechnic UniversityCompleted
-
Federal University of São PauloCompletedKNEE OSTEOARTHRITISBrazil
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
Thammasat UniversityCompletedPrimary Knee OsteoarthritisThailand
-
Galderma R&DCompletedUnilateral Knee OsteoarthritisUnited Kingdom
-
National Yang Ming UniversityFar Eastern Memorial HospitalCompletedMedial Knee OsteoarthritisTaiwan
-
Hanlim Pharm. Co., Ltd.CompletedKnee OsteoarthritisKorea, Republic of
Clinical Trials on PB125
-
VA Office of Research and DevelopmentRecruitingPeripheral Artery Disease (D058729) | Oxidative Stress (D018384) | Inflammation (D007249)United States